Topics

Cancer vaccines and immunotherapy

Cancer Immunotherapy Intercellular Communication & Diseases Tumor Microenvironment Immunogenic Cell Death

Therapeutic cancer vaccines aim to generate or amplify immune responses against antigens expressed by an established tumor. Platforms include peptides, proteins, nucleic acids, viral vectors, dendritic cells, and tumor-derived material. Earlier vaccines often targeted shared tumor-associated antigens, which can be limited by immune tolerance and normal-tissue expression. Genomic sequencing enabled personalized neoantigen vaccines directed at mutations absent from healthy cells, while mRNA technology made rapid, multivalent manufacturing more practical. Vaccines are generally better at priming and broadening T-cell repertoires than at reversing every suppressive feature of advanced tumors, so current development emphasizes rational combinations and treatment of low-burden or minimal residual disease The distinction between prevention and therapy is important: an established cancer has already undergone immune editing and built mechanisms that resist newly primed cells[1][2][3].

An effective vaccine must deliver antigen to professional antigen-presenting cells together with danger or adjuvant signals. Dendritic cells process antigen, present peptides on MHC class I and II, provide costimulation, and expand CD8 and CD4 T cells. The resulting clones must traffic to tumor, recognize sufficient peptide–MHC, and avoid exhaustion. Neoantigen selection requires accurate mutation calling, expression evidence, HLA typing, processing and binding prediction, and confirmation of immunogenicity. mRNA can encode multiple antigens and activates innate sensing, but formulation and dose must balance translation with inflammation. Delivery to the wrong tissue or without adequate maturation may produce weak or tolerogenic responses Both class I and class II epitopes can be valuable because helper T cells sustain cytotoxic responses and coordinate broader immune-cell recruitment[1][2][3].

Applications include personalized vaccines after surgery, combinations with PD-1 blockade, dendritic-cell vaccination, and shared-antigen approaches when a reliable target is common across patients. Checkpoint inhibitors can sustain vaccine-expanded T cells, while radiation or selected chemotherapy may release additional antigens. A multivalent vaccine can address tumor heterogeneity, but subclonal or poorly expressed mutations may contribute little. Manufacturing time matters in aggressive disease, and patient-specific products require coordinated sequencing, bioinformatics, release testing, and clinical scheduling. Toxicity is often less acute than with cell therapy, yet autoimmunity, inflammatory reactions, and off-target antigen selection remain relevant Clinical development must also distinguish failure to prime from failure of primed cells to enter or recognize the tumor, since the corrective intervention differs[1][3].

Key gaps include reliable epitope prioritization, proof of tumor trafficking, and determination of the best disease stage. Immune responses measured in blood do not guarantee recognition of tumor cells, especially when antigen presentation is defective. Trials should connect vaccine-induced clonotypes with tumor infiltration, target-cell killing, and recurrence outcomes. Shared benchmarks for prediction pipelines and prospective validation can reduce false candidates. Improved lymph-node delivery, self-amplifying or circular RNA formats, and coordinated CD4 and CD8 antigen design may increase potency. Cancer vaccines are most likely to succeed as part of a system that combines precise antigen selection, effective dendritic-cell activation, relief of local inhibition, and enough time for adaptive immunity to mature Durable memory, breadth against multiple clones, and compatibility with standard therapy may ultimately matter more than the magnitude of one early blood response. Efficient manufacturing must still preserve sequence accuracy and product consistency[1][2][3].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Peptides
  • Screening Libraries
  • Inhibitory Antibodies
  • Reference Standards
  • Induced Disease Models Products
  • GMP Small Molecules
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-17589 Chloroquine phosphate
Chloroquine phosphate is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine phosphate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM).
Parasite   Autophagy   SARS-CoV   Toll-like Receptor (TLR)   HIV   Antibiotic  
Pancreatic Cancer   Viral Infection   Parasitic Infection   Pain   SARS-CoV-2 Infection   Rheumatoid Arthritis  
1344
HY-17589A Chloroquine
Chloroquine is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM).
Parasite   Autophagy   SARS-CoV   Toll-like Receptor (TLR)   HIV   Antibiotic  
Breast Cancer   Pancreatic Cancer   Viral Infection   Parasitic Infection   Pain   SARS-CoV-2 Infection   Rheumatoid Arthritis  
1344
HY-D1056 Lipopolysaccharides, from E. coli O55:B5
Lipopolysaccharides, from E. coli O55:B5 (LPS, from Escherichia coli (O55:B5)) are endotoxins and TLR4 activators extracted from Escherichia coli (E. coli O55:B5) and are classified as S (smooth) type LPS. Lipopolysaccharides, from E. coli O55:B5 possess the typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Lipopolysaccharides, from E. coli O55:B5 activate TLR-4 in immune cells, exhibit high pyrogenicity, and demonstrate dose and serotype specificity. Lipopolysaccharides, from E. coli O55:B5 can be widely used to induce cellular inflammation and establish animal models related to inflammation.
It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.

Source: surface of Gram-negative bacteria

Toll-like Receptor (TLR)  
Cancer   Pain   Autoimmune Disease   Escherichia Coli Infection  
616
HY-11109 Resatorvid
Resatorvid (TAK-242) is a selective Toll-like receptor 4 (TLR4) inhibitor. Resatorvid inhibits NO, TNF-α and IL-6 production with IC50s of 1.8 nM, 1.9 nM and 1.3 nM, respectively. Resatorvid downregulates expression of TLR4 downstream signaling molecules MyD88 and TRIF. Resatorvid inhibits autophagy and plays pivotal role in various inflammatory diseases.
Toll-like Receptor (TLR)   TNF Receptor   Interleukin Related   Autophagy  
Prostate Cancer   Pain   Digestive System Inflammation   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
536
HY-100573 Necrosulfonamide
Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.
Mixed Lineage Kinase   Necroptosis   Pyroptosis   Caspase   NOD-like Receptor (NLR)   Keap1-Nrf2   TNF Receptor   Interleukin Related   NO Synthase   Heme Oxygenase (HO)  
Digestive System Disease   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Depression   Digestive System Inflammation   Cardiovascular Disease   Parkinson's Disease   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
147
HY-13740 Resiquimod
Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α.
Toll-like Receptor (TLR)   HCV  
Prostate Cancer   Viral Infection   Depression   Pain   Autoimmune Disease   SARS-CoV-2 Infection   Hepatitis C Virus Infection  
120
HY-W031727 Hydroxychloroquine
Hydroxychloroquine (HCQ) is a synthetic oral antimalarial drug that can be used in the study of malaria and autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. Hydroxychloroquine is a potent autophagic flux inhibitor with antiviral activity (such as SARS-CoV-2 virus) that inhibits Toll-like receptor 7/9 (TLR7/9) signaling.
Parasite   Toll-like Receptor (TLR)   SARS-CoV   Autophagy  
Prostate Cancer   Pancreatic Cancer   Viral Infection   Parasitic Infection   Pain   Rheumatoid Arthritis  
95
HY-L031 Small Molecule Immuno-Oncology Compound Library
Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines. MCE Small Molecule Immuno-Oncology Compound Library offers 831 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

Disease Focused Libraries

88
HY-L073 Anti-Hepatitis C Virus Compound Library
Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle. MCE offers a unique collection of 394 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Disease Focused Libraries

83
HY-L105 Peptide Library
Peptides are a group of biologically active substances that are involved in various cellular functions of organisms. Peptides are often used in functional analysis, vaccine research and especially in the field of drug research and development. At present, more than 80 peptide drugs have reached the market for a wide range of diseases, including diabetes, cancer, osteoporosis, multiple sclerosis, HIV infection and chronic pain. MedChemExpress (MCE) offers a comprehensive collection of 2,647 peptides, including bioactive peptides, amino acid derivatives, and blocking peptides. MCE Peptide Library can be used for peptide library screening, peptide drug discovery, vaccine development, target verification, structural activity research, etc.

Structure Classified Libraries

83
HY-L110 Cyclic Peptide Library
Cyclic peptides are polypeptide chains taking cyclic ring structure, which exhibit diverse biological activities, such as antibacterial activity, immunosuppressive activity and anti-tumor activity. Cyclic peptides, with the features of good binding affinity, target selectivity and low toxicity, show great success as therapeutics. Multiple cyclic peptides are currently in clinical use, for examples, gramicidin and tyrocidine with bactericidal activity, cyclosporin A with immunosuppressive activity, and vancomycin with antibacterial activity. Furthermore, cyclic peptides usually have the sufficient size and a balanced conformational flexibility/rigidity for binding to flat protein-protein interaction (PPI) interfaces, which have potential to develop PPI drugs. MCE offers a unique collection of 100 cyclic peptides, all of which have good bioactivities. MCE Cyclic Peptide Library is a powerful tool for drug discovery and PPI inhibitor screening.

Structure Classified Libraries

83
HY-L156 Autoimmune Disease Compound Library
Autoimmune disease is a pathological disease characterized by inflammatory disorders targeting autoantigens. The routine treatment of autoimmune diseases suppresses general immune function to regulate uncontrolled inflammation. The current targeted immunotherapy suppresses the main pro-inflammatory signaling pathways by blocking inflammatory cytokines, cell surface molecules, and intracellular kinases. As key participants in innate immunity, macrophages and dendritic cells (DCs) are crucial for Ag presentation and pro-inflammatory cytokine production, such as TNF and IL-1 β、 IL-6, IL-23, B cell activating factor (BAFF), and the proliferation-inducing ligand (APRIL, also known as TNFSF13A). MCE designs a unique collection of 1,040 autoimmune disease-related compounds, covering multiple targets and subtypes, such as TNF Receptor, IFNAR, JAK, Btk, TLR, IL-6, IL-17, IL-23, etc. It is a useful tool for screening autoimmune disease drugs.

Disease Focused Libraries

83
HY-L172 Immunopotentiator Compound Library
Immunity refers to the ability of the body to resist the invasion of pathogenic microorganisms and resist a variety of diseases. Immunocompromised will inevitably lead to a series of diseases. Immunopotentiator are a class of compounds that enhance immune function and induce immune response. Immunopotentiator can activate the proliferation and differentiation of one or more kinds of immune active cells in the body, promote the secretion of lymphocytes, and then enhance the immune function of the body. Immunopotentiator are mainly used in the treatment of tumors, infectious diseases and immunodeficiency diseases. In addition, immunopotentiator are often used as adjuvants in combination with vaccine antigens to enhance the immunogenicity of vaccines. MCE designs a unique collection of 150 compounds with definite or potential Immunopotentiating effect, mainly targeting the NOD-like Receptor (NLR), Toll-like Receptor (TLR), NF-κB, etc. It is an effective tool for development and research of anti-cancer, anti-infectious diseases and anti-immunodeficiency diseases compounds.

Compound Characteristic Classified Libraries

83
HY-L251 Ionizable Lipid Compound Library
Ionizable lipids are a class of specialized, functional lipid molecules with pH-sensitive charge characteristics. They are primarily divided into two major categories: ionizable cationic lipids and ionizable anionic lipids, though the term typically specifies ionizable cationic lipids within the biomedical field. Structurally, these lipids consist of an ionizable hydrophilic headgroup, a biodegradable linker, and hydrophobic tails. Their primary application is serving as the key delivery vehicle in lipid nanoparticles (LNPs) to encapsulate negatively charged nucleic acid macromolecules, such as mRNA vaccines, siRNA therapeutics, and CRISPR gene-editing components. In a physiological, neutral environment, they remain electrically neutral to minimize systemic toxicity and prolong circulation time. Upon entering the acidic microenvironment of cellular endosomes, however, they undergo protonation to become positively charged, thereby inducing membrane fusion and enabling the highly efficient intracellular release of the nucleic acid cargo. Consequently, they serve as the technological cornerstone for bringing nucleic acid therapies into clinical application. To accelerate the translational process of cutting-edge nucleic acid drugs, MCE has meticulously constructed an ionizable lipid compound library containing 93 high-performance molecules, aiming to provide researchers and pharmaceutical professionals with a high-throughput, multi-dimensional lipid screening platform.

Structure Classified Libraries

83
HY-135748 Polyinosinic-polycytidylic acid sodium
Polyinosinic-polycytidylic acid (Poly(I:C)) sodium is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid sodium can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid sodium can directly trigger cancer cells to undergo apoptosis.
RIG-I-like receptor (RLR)   Toll-like Receptor (TLR)   Apoptosis  
Cancer   Digestive System Disease   Pain   Autoimmune Disease   Digestive System Inflammation   Lung Fibrosis  
75
HY-N0822 Shikonin
Shikonin is a major component of a Chinese herbal medicine named zicao. Shikonin is a potent TMEM16A chloride channel inhibitor with an IC50 of 6.5 μM. Shikonin is a specific pyruvate kinase M2 (PKM2) inhibitor and can also inhibit TNF-α and NF-κB pathway. Shikonin decreases exosome secretion through the inhibition of glycolysis. Shikonin inhibits AIM2 inflammasome activation.
Exosomes   Chloride Channel   Pyruvate Kinase   NF-κB   TNF Receptor   HIV   AIM2  
Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Viral Infection   Depression   Pain   Digestive System Inflammation   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
74
HY-107202 Polyinosinic-polycytidylic acid
Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid can directly trigger cancer cells to undergo apoptosis.
RIG-I-like receptor (RLR)   Toll-like Receptor (TLR)   PKD   HSP   Bcl-2 Family   Interleukin Related   Apoptosis  
Infection   Digestive System Disease   Prostate Cancer   Pain   Digestive System Inflammation   Lung Fibrosis   Rheumatoid Arthritis  
73
HY-B1618 Corticosterone
Corticosterone (17-Deoxycortisol) is an orally active and adrenal cortex-produced glucocorticoid, which plays an important role in regulating neuronal functions of the limbic system (including hippocampus, prefrontal cortex, and amygdala). Corticosterone increases the Rab-mediated AMPAR membrane traffic via SGK-induced phosphorylation of GDI. Corticosterone also interferes with the maturation of dendritic cells and shows a good immunosuppressive effect.
Glucocorticoid Receptor   Endogenous Metabolite   iGluR  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease   Pain   SARS-CoV-2 Infection   Osteoarthritis  
71
HY-A0003 Lenalidomide
Lenalidomide (CC-5013) is an orally active immunomodulatory agent that binds CRBN as a molecular glue to alter substrate specificity, inducing ubiquitination and proteasome-dependent degradation of IKZF1, IKZF3 and CK1α. Lenalidomide induces apoptosis by degrading IKZF1/3, and activates p53 by degrading CK1α. Lenalidomide promotes IL-2 release and effector functions of CD8+ T/NK cells, while inhibiting TNF-α secretion and M1-type pyroptosis. Lenalidomide can be used in research related to hematological malignancies, acute liver failure and acute kidney injury.
Molecular Glues   Ligands for E3 Ligase   IKZF Family   Casein Kinase   Apoptosis   Pyroptosis   MDM-2/p53   TNF Receptor  
Inflammation or Immune System Disease   Renal Disease   Chronic Lymphocytic Leukemia   Diffuse Large B-cell Lymphoma   Multiple Myeloma   Myelodysplastic Syndrome   Liver Failure  
63
HY-B0180 Imiquimod
Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19.
Toll-like Receptor (TLR)   Autophagy   SARS-CoV   HSV  
Inflammation or Immune System Disease   Metastatic Breast Cancer   SARS-CoV-2 Infection  
62
HY-123606 GSK484
GSK484 is a PAD4 inhibitor that effectively inhibits protein citrullination and the formation of neutrophil extracellular traps (NETs) by blocking the catalytic activity of PAD4. GSK484 suppresses the production of histone H3, MHC-I expression, CD8+ T cell activation, proliferation and inflammatory cytokine release. GSK484 reduces inflammation and bone destruction in collagen-induced rheumatoid arthritis, alleviates pain and mast cell activation in sickle cell disease, and improves myocardial ischemia-reperfusion injury and experimental colitis. In addition, GSK484 restores intestinal microbial homeostasis by reversing ferroptosis-induced dysbiosis. GSK484 can be used to study the disease mechanisms of rheumatoid arthritis, sickle cell disease, thrombosis, myocardial injury, colitis and other conditions.
Protein Arginine Deiminase   MHC  
Digestive System Disease   Colitis   Sickle Cell Disease   Cardiomyopathy   Rheumatoid Arthritis  
57
HY-N0182 Fisetin
Fisetin is a natural flavonol found in many fruits and vegetables with various benefits, such as antioxidant, anticancer, neuroprotection effects.
Sirtuin   PPAR   TNF Receptor  
Digestive System Disease   Prostate Cancer   Viral Infection   Depression   Digestive System Inflammation   SARS-CoV-2 Infection   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
35
HY-P9970 Infliximab
Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research.
The component ratio of this product is Active ingredient : Excipients = 9 : 47.

Species: Human

TNF Receptor  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease   Lung Cancer   Breast Cancer  
30
HY-P1489A OVA Peptide(257-264) TFA
OVA Peptide(257-264) TFA is a class I (Kb)-restricted peptide epitope of OVA, an octameric peptide can be from ovalbumin presented by the class I MHC molecule, H-2Kb.
MHC  
Inflammation or Immune System Disease  
25
HY-P1489 OVA Peptide(257-264)
OVA Peptide(257-264) is a class I (Kb)-restricted peptide epitope of OVA, an octameric peptide can be from ovalbumin presented by the class I MHC molecule, H-2Kb.
MHC  
Inflammation or Immune System Disease  
25
HY-153808 Complete Freund's adjuvant (CFA)
Complete Freund's adjuvant (CFA) is an immunoadjuvant emulsified with antigen by its discoverer Jules T. Freund to enhance an animal's immune response to an antigen. Complete Freund's adjuvant (CFA) is also an inducer of the Th1 immune response and a ligand of TLRs. Complete Freund's adjuvant (CFA) contains heat-killed inactive tuberculosis bacilli and consists of a paraffin oil-in-water emulsion. Complete Freund's adjuvant (CFA) stimulates a strong and durable immune response and can be used to induce persistent inflammatory pain models in mice, experimental autoimmune myocarditis (EAM) models, and more. Incomplete Freund's adjuvant (IFA) (HY-153808A) is another type of Freund's Adjuvant that stimulates a weaker immune response.
Toll-like Receptor (TLR)  
Inflammation or Immune System Disease  
25
HY-P9908 Adalimumab
Adalimumab is a human monoclonal IgG1 antibody targeting tumour necrosis factor α (TNF-α).

Species: Human

TNF Receptor   Bacterial  
Cancer   Autoimmune Disease  
20
HY-P1846 Jagged-1 (188-204)
Jagged-1 (188-204) is a fragment of the Jagged-1 (JAG-1) protein with Notch agonist activity. JAG-1 is a Notch ligand highly expressed in cultured and primary multiple myeloma (MM) cells. JAG-1 induces maturation of monocyte-derived human dendritic cells.
Notch  
Cancer  
19
HY-P1846A Jagged-1 (188-204) TFA
Jagged-1 (188-204) TFA is a fragment of the Jagged-1 (JAG-1) protein with Notch agonist activity. JAG-1 is a Notch ligand highly expressed in cultured and primary multiple myeloma (MM) cells. JAG-1 induces maturation of monocyte-derived human dendritic cells.
Notch  
Cancer  
19
HY-108847 Etanercept
Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis.
TNF Receptor   Bacterial  
Cancer   Rheumatoid Arthritis  
16
HY-107632 GYY4137
GY4137 is a sustained-release H2S donor possessing vasodilatory, antihypertensive, and anti-inflammatory activities. GY4137 can inhibit cell growth, induce apoptosis, and cause cell cycle arrest by blocking the STAT3 pathway, demonstrating potent anticancer activity.
Apoptosis   STAT   NF-κB   NO Synthase   COX   TNF Receptor   Interleukin Related  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
8
HY-113962 7α,25-Dihydroxycholesterol
7α, 25-dihydroxycholesterol (7α,25-OHC) is a potent and selective agonist and endogenous ligand of the orphan GPCR receptor EBI2 (GPR183). 7α, 25-dihydroxycholesterol is highly potent at activating EBI2 (EC50=140 pM; Kd=450 pM). 7α, 25-dihydroxycholesterol can serve as a chemokine directing migration of B cells, T cells and dendritic cells.
EBI2/GPR183   Endogenous Metabolite  
Inflammation or Immune System Disease  
5
HY-123941 FKBP12 PROTAC dTAG-7
FKBP12 PROTAC dTAG-7 (dTAG-7) is a FKBP12F36V PROTAC degrader. FKBP12 PROTAC dTAG-7 binds FKBP12F36V and CRBN to form a complex, mediating degradation via the ubiquitin-proteasome system. FKBP12 PROTAC dTAG-7 mediates the degradation of FKBP12F36V-tagged nuclear and cytoplasmic proteins, including BRD4, HDAC1, EZH2, MYC, PLK1, KRASG12V, and antigen fusion proteins. FKBP12 PROTAC dTAG-7 enhances MHC class I antigen presentation. FKBP12 PROTAC dTAG-7 is applicable to leukemia-related research.
PROTACs   FKBP   Epigenetic Reader Domain   HDAC   Histone Methyltransferase   c-Myc   Polo-like Kinase (PLK)   Ras   MHC  
Leukemia/Lymphoma/Myeloma  
4
HY-N4087 Platycodin D2
Platycodin D2 is an orally active triterpenoid saponin found in Platycodon grandiflorum. Platycodin D2 induces mitophagy in cancer cells through NIX, thereby activating the P21/CyclinA2 pathway and promoting cell senescence. Platycodin D2 induces mitochondrial dysfunction, enhances autophagy, inhibits hepatocellular carcinoma cell proliferation, and exhibits anti-tumor activity against multiple cancer cell types. Platycodin D2 promotes mRNA expression of T-bet, GATA-3, Th1 cytokines IL-2 and IFN-γ, and Th2 cytokines IL-4 and IL-10, enhances splenocyte proliferation, and acts as a vaccine adjuvant with low rabbit red blood cell hemolytic activity. Platycodin D2 induces mitochondrial ROS production, incomplete autophagy, and ferroptosis to inhibit breast cancer cell proliferation. Platycodin D2 can be used for the research of cancer, inflammation and immunology.
Mitophagy   Autophagy   Ferroptosis   Interleukin Related   IFNAR   Reactive Oxygen Species (ROS)  
Cancer   Inflammation or Immune System Disease  
3
HY-109520 Glatiramer acetate
Glatiramer acetate, a synthetic analogue of myelin basic protein and an immunomodulating agent, inhibits Experimental autoimmune encephalomyelitis (EAE), and can be used for the research of multiple sclerosis. Glatiramer acetate exhibits strong and promiscuous binding to MHC molecules and consequent competition with various myelin antigens for their presentation to T cells. A further aspect of its action is potent induction of specific suppressor cells of the T helper 2 (Th2) type that migrate to the brain and lead to in situ bystander suppression.
MHC  
Cancer   Experimental Autoimmune Encephalomyelitis   Experimental Autoimmune Encephalomyelitis  
2
HY-114041 Resolvin E1
Resolvin E1 (RvE1), a potent endogenous pro-resolving mediator of inflammation, is derived from omega-3 fatty acid eicosapentaenoic acid (EPA). Resolvin E1 is endogenously biosynthesized from EPA in the presence of Aspirin during the spontaneous resolution phase of acute inflammation, where specific cell-cell interactions occur. Resolvin E1 possesses unique counterregulatory actions that inhibit polymorphonuclear leukocyte (PMN) transendothelial migration. Resolvin E1 also acts as a potent inhibitor of leukocyte infiltration, dendritic cell migration, and IL-12 production.
Endogenous Metabolite  
Inflammation or Immune System Disease  
2
HY-P99931 Epcoritamab
Epcoritamab (GEN3013) is an bispecific IgG1 antibody redirecting T-cells toward CD3×CD20+ tumor cells. Epcoritamab induces potent T-cell-mediated cytotoxicity towards B-cell NHL cell lines.

Species: Human

CD3   CD20  
Chronic Lymphocytic Leukemia   Non-Hodgkin Lymphoma   Diffuse Large B-cell Lymphoma  
2
HY-P10869 dCNP
dCNP binds to NPR-B/C receptor, activates cGMP signaling pathway, and regulates vascular function. dCNP exhibits anti-hypoxia property through downregulation of hypoxia-related genes expressions like HIF1α and HIF2α. dCNP inhibits the induction of tumor stroma and exhibits anti-fibrosis activity. dCNP upregulates CTLs, NK cells, and conventional type 1 dendritic cells in tumors, and activates immune responses.
Natriuretic Peptide Receptor (NPR)  
Cancer   Inflammation or Immune System Disease  
1
HY-P991257 MK-1966
MK-1966 is an anti-IL-10 antibody. MK-1966 inhibits secretion of cytokines from activated macrophages, production of CC and CXC chemokines, and a TH1 response, down-regulates MHC and costimulatory molecules on dendritic cells (DCs), and induces regulatory T cells. MK-1966 can be used for the research of cancer , such as gastric cancer.

Species: Human

Interleukin Related   CXCR   MHC  
Gastric Cancer  
1
HY-N0307 Ciwujianoside B
Ciwujianoside B is an orally active, blood-brain barrier penetrable radioprotective agent and memory enhancer. Ciwujianoside B reduces radiation-induced DNA damage, cell cycle arrest and apoptosis, downregulates NF-κB and the Bax/Bcl-2 ratio, and enhances the proliferative capacity of bone marrow cells. Ciwujianoside B enhances object recognition memory in normal mice and induces dendritic extension in primary cultured cortical neurons. Ciwujianoside B can be used in studies related to hematopoietic system radiation injury and memory enhancement.
Bcl-2 Family   NF-κB   DNA/RNA Synthesis   Apoptosis  
Blood or Cardio-cerebrovascular Disease   Neurodegenerative Disease  
1
HY-19480 Ulodesine
Ulodesine (BCX4208) is a purine nucleoside phosphorylase (PNP) inhibitor, with an IC50 of 2.293 nM against human PNP, and low nanomolar IC50 values against mouse, rat and monkey PNP. Ulodesine blocks the production of uric acid precursors, reduces serum uric acid levels, clears accumulated uric acid in the blood, and elevates the levels of purine nucleosides including guanosine. Ulodesine reduces the counts of total lymphocytes, T lymphocytes and lymphocyte subsets, inhibits the proliferation of cancer cells and activated lymphocytes, and enhances vaccine immune responses. Ulodesine can be used in research related to hyperuricemia and gout.
Phosphatase  
Inflammation or Immune System Disease   Hyperuricemia   Gout  
1
HY-P1684 Peptide P60
Peptide P60 is a FOXP3 inhibitor. Peptide P60 reduces the nuclear translocation of FOXP3 and impairs FOXP3-mediated inhibition of NF-κB and NFAT activity. Peptide P60 inhibits the immunosuppressive activity of regulatory T cells and restores the proliferation and activation of effector T cells. Peptide P60 induces lymphoproliferative autoimmune syndrome in neonatal ICR mice and reduces the number of CD4+CD25+Foxp3+ T cells in the spleen. Peptide P60 enhances the efficacy of AH1 (HY-P4193) peptide vaccine and recombinant adenovirus-based HCV NS3 vaccine in BALB/c mice, including protective effects against CT26 tumor implantation. Peptide P60 can be used in studies related to tumor immunity, viral infection and lymphoproliferative autoimmune syndrome.
FOXP   NF-κB   Nuclear Factor of activated T Cells (NFAT)  
Cancer   Infection   Inflammation or Immune System Disease  
1
HY-P99742 Mitazalimab
Mitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid microenvironment.

Species: Human

TNF Receptor  
Cancer  
1
HY-P99300 Ligelizumab
Ligelizumab (QGE 031) is a humanized high-affinity anti-immunoglobulin IgE monoclonal antibody. Ligelizumab selectively inhibits the binding of IgE to the high-affinity receptor FcεRI, while the inhibitory effect on the low-affinity receptor CD23 is weak. Ligelizumab can inhibit the activation of effector cells such as mast cells and Basophil, while reducing the production of IgE by B cells, and restoring the IFN-α production and regulatory T cell (Treg) induction function of plasmacytoid dendritic cells (pDC). Ligelizumab can be used in the study of allergic diseases (such as chronic spontaneous urticaria, allergic asthma).

Species: Human

Fc Receptor (FcR)  
Allergic Asthma   Urticaria  
1
HY-P990680 Anti-Mouse CD40 Antibody (FGK4.5/FGK45)
Anti-Mouse CD40 Antibody (FGK4.5/FGK45) is an agonistic rat-derived IgG2a monoclonal antibody targeting mouse CD40. Anti-Mouse CD40 Antibody (FGK4.5/FGK45) enhances T cells responses, dendritic cells maturation and NK cells activation. Anti-Mouse CD40 Antibody (FGK4.5/FGK45) can be used for the researches of cancer, infection, inflammation and immunology, such as CT26 tumor, vesicular stomatitis virus (VSV) infection and transplantation.

Species: Mouse

Transmembrane Glycoprotein   TNF Receptor  
Inflammation or Immune System Disease   Colorectal Cancer   Viral Infection  
1
HY-126855 Cholic acid 7-sulfate
Cholic acid 7-sulfate (7-Sulfocholic acid) is a selective agonist targeting TGR5 (EC50=0.17 μM) and a ligand for MHC class I-related protein (MR1). As a gut-restricted TGR5 agonist, cholic acid 7-sulfate binds to TGR5 on enteroendocrine L cells, induces GLP-1 secretion, and improves glucose tolerance in a TGR5-dependent manner. Cholic acid 7-sulfate also acts as an endogenous ligand for MR1, promoting the survival of mucosal-associated invariant T cells MAIT and the expression of homeostatic gene signatures, affecting MAIT cell development and function. Cholic acid 7-sulfate is mainly used in the research of diabetes and MAIT cell-related immune regulation.
G protein-coupled Bile Acid Receptor 1   MHC  
Glucose Metabolism   Obesity  
1
HY-P99901 Sibeprenlimab
Sibeprenlimab (VIS649) is a humanized IgG2 monoclonal antibody which inhibits a proliferation-inducing ligand (APRIL). Sibeprenlimab suppresses pathogenic immunoglobulins (IgA and IgM), while preserving antibody responses to mRNA-based vaccines against SARS-COV-2. Sibeprenlimab reduces urinary protein-to-creatinine ratio (UPCR) and glomerular filtration rate (GFR). Sibeprenlimab is promising for the research of IgA nephropathy (IgAN).

Species: Human

SARS-CoV  
Cancer   Inflammation or Immune System Disease  
1
HY-P99394 Talquetamab
Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and CD3 to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity.

Species: Human

CD3  
Cancer  
1
HY-P99592 Solitomab
Solitomab (AMG 110) is a bispecific anti-CD3 and anti-epithelial-cell-adhesion-molecule (EpCAM) antibody. Solitomab can be used for the research of primary uterine and ovarian carcinosarcoma cancer.

Species: Human

CD3  
Ovarian Cancer  
1
HY-P99033 Mosunetuzumab
Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs). The Fc region of Mosunetuzumab incorporates a "knob-into-hole" structural modification and an N297G point mutation to achieve heterodimerization and eliminate Fc glycosylation, thereby effectively silencing antibody effector functions.

Species: Human

CD20   CD3  
Cancer Immunology   Non-Hodgkin Lymphoma  
1
HY-P99024 Glofitamab
Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell non-Hodgkin lymphoma (B-NHL).

Species: Human

CD20   CD3  
Cancer   Inflammation or Immune System Disease  
1
HY-P990007 Tulisokibart
Tulisokibart (PRA023) is a humanized IgG1-κ monoclonal antibody. Tulisokibart targets to TNFSF15/TL1A. Tulisokibart can be used to study a variety of inflammatory/fibrotic diseases, such as Crohn's Disease (CD) and ulcerative colitis.

Species: Human

TNF Receptor  
Digestive System Inflammation   Crohn's Disease   Ulcerative Colitis  
1
HY-114041S Resolvin E1-d4
Resolvin E1-d4 (RvE1-d4) is deuterium labeled Resolvin E1. Resolvin E1 (RvE1), a potent endogenous pro-resolving mediator of inflammation, is derived from omega-3 fatty acid eicosapentaenoic acid (EPA). Resolvin E1 is endogenously biosynthesized from EPA in the presence of Aspirin during the spontaneous resolution phase of acute inflammation, where specific cell-cell interactions occur. Resolvin E1 possesses unique counterregulatory actions that inhibit polymorphonuclear leukocyte (PMN) transendothelial migration. Resolvin E1 also acts as a potent inhibitor of leukocyte infiltration, dendritic cell migration, and IL-12 production.
Isotope-Labeled Compounds   Endogenous Metabolite  
Inflammation or Immune System Disease  
/
HY-P3315 Onilcamotide
Onilcamotide (RV001) is a C-terminal peptide of RhoC protein. Onilcamotide is a cancer vaccine and has potential immunomodulating and antineoplastic activities.
Others  
Inflammation or Immune System Disease  
/
HY-156087G Cholicamideβ (GMP)
Cholicamideβ (GMP) is a GMP grade of Cholicamideβ. Cholicamideβ (compound 6) is a self-assembling, small molecule, cancer vaccine adjuvant. Cholicamideβ can form virus-like particles with low cytotoxicity. Cholicamideβ, upon binding to peptide antigens, enhances antigen presentation by dendritic cells and induces antigen-specific T cells. Cholicamideβ can induce apoptosis and necrosis.
Apoptosis   Necroptosis  
/
HY-W016773S 1,10-Decanediol-d20
1,10-Decanediol-d20 is the deuterium labeled 1,10-Decanediol. 1,10-Decanediol is a diol compound that can react with α-ketoglutarate (aKG) to generate polymeric microparticles (termed paKG MPs) for the sustained release of aKG, thereby promoting immunosuppressive regulation. Additionally, paKG MPs can bind to dendritic cells (DCs), reducing their glycolysis and mitochondrial respiration in vitro. These metabolic changes lead to the modulation of MHC-II and CD86 expression in DCs and alter the frequency of regulatory T cells (Tregs) as well as T-helper type 1/2/17 cells in vitro. 1,10-Decanediol can be used in research within the field of immunometabolism. can be used as a surfactant/stabilizer in the synthesis of nanomaterials.
Isotope-Labeled Compounds  
/
HY-P11014 SjDX5-53 control peptide
SjDX5-53 control peptide is a control peptide of the TLR2 activator SjDX5-53 (HY-P10982) that does not target a specific receptor and does not modulate regulatory T cells (Tregs) or dendritic cells. SjDX5-53 control peptide can be used to exclude nonspecific effects and help verify the specific role of SjDX5-53 in inducing Tregs and alleviating autoimmune diseases. SjDX5-53 control peptide is used in the study of autoimmune diseases such as colitis and psoriasis.
Toll-like Receptor (TLR)  
Inflammation or Immune System Disease  
/
HY-W583868S 1-Palmitoyl-2-oleoyl-sn-glycero-3-PE-d62
1-Palmitoyl-2-oleoyl-sn-glycero-3-PE-d62 (1,2-POPE-d62) is the deuterium labeled 1-Palmitoyl-2-oleoyl-sn-glycero-3-PE. 1-Palmitoyl-2-oleoyl-sn-glycero-3-PE (1,2-POPE; 16:0-18:1 PE) is a phosphatidylethanolamine (PE) lipid. 1-Palmitoyl-2-oleoyl-sn-glycero-3-PE can induce lipid bilayer to form a hexagonal phase (HII) structure in an acidic environment and promote membrane fusion. 1-Palmitoyl-2-oleoyl-sn-glycero-3-PE can enhance the endosomal escape ability of lipid nanoparticles (LNPs) and improve the cellular delivery efficiency of nucleic acid drugs such as mRNA. 1-Palmitoyl-2-oleoyl-sn-glycero-3-PE can be used for LNP carrier targeting of gene therapy and mRNA vaccines.
Isotope-Labeled Compounds  
/
HY-183208 Ki-67 peptide/BSA
Ki-67 peptide/BSA is an antigen-adjuvant conjugate conjugate of Ki-67 peptide and BSA. By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and can enhance cross-presentation and the production of antigen-specific T cells.
Biochemical Assay Reagents  
/
HY-P991510 CDX-1140
CDX-1140 is a fully human IgG monoclonal antibody and CD40 agonist, with a Kd value of 0.01 nM against human targets. The epitope of CDX-1140 locates at CD40 CRD1 and avoids the CD40L binding site. It activates DCs and B cells, drives NF-κB reporter gene activation, exhibits agonist activity independent of FcR cross-linking, and shows a synergistic effect with recombinant CD40L. CDX-1140 does not induce systemic cytokine release, exerts direct and immune-mediated anti-tumor activity in tumor xenografts, and has favorable safety profiles. When used as a local vaccine adjuvant in combination with 6MHP+mBRAF+poly-ICLC, CDX-1140 increases the number of DC-LAMP+ DCs and induces Th1 CD4+ responses in high-risk melanoma. CDX-1140 can be used in studies related to B-cell lymphoma, bladder cancer and high-risk melanoma.

Species: Human

TNF Receptor  
Bladder Cancer   Leukemia/Lymphoma/Myeloma   Melanoma  
/
HY-P10838 PL120131
PL120131 is a PD-1 antagonist, can specifically blocking the interaction between PD-1 and PD-L1, thereby effectively inhibiting the PD-1-mediated apoptosis signaling pathway. PL120131 rescues lymphocytes from apoptosis, maintains the survival and activity of T cells, and induces cytotoxic T lymphocytes to exert killing effects and recognize macrophages and dendritic cells. PL120131 can be used in research related to breast cancer and various malignant tumors.
PD-1/PD-L1   Apoptosis  
Breast Cancer  
/
HY-P3129 KRAS G13D peptide, 25 mer
KRAS G13D peptide, 25 mer, a KRAS activating oncogene mutation peptide, is an immune potentiator extracted from patent WO2018144775A1. KRAS G13D peptide, 25 mer can be used to prepare KRAS vaccine.
Ras  
Cancer   Inflammation or Immune System Disease  
/
HY-N19910 Dihydroeleutherinol-8-O-β-D-glucopyranoside
Dihydroeleutherinol-8-O-β-D-glucopyranoside is an anti-inflammatory agent. Dihydroeleutherinol-8-O-β-D-glucopyranoside exists in the rhizomes of Eleutherine bulbosa and acts as a pro-inflammatory cytokine inhibitor. Dihydroeleutherinol-8-O-β-D-glucopyranoside inhibits the production of IL-12 p40 (IC50 = 1.0 μM) and IL-6 (IC50 = 5.0 μM) in lipopolysaccharide-stimulated dendritic cells. At the tested concentrations, Dihydroeleutherinol-8-O-β-D-glucopyranoside does not inhibit the production of TNF-α in lipopolysaccharide-stimulated dendritic cells and shows no cytotoxicity against dendritic cells. Dihydroeleutherinol-8-O-β-D-glucopyranoside can be used in studies related to rheumatoid arthritis.
Interleukin Related  
Rheumatoid Arthritis  
/
HY-114041S1 Resolvin E1-d4-1
Resolvin E1-d4-1 is the deuterium labeled Resolvin E1. Resolvin E1 (RvE1), a potent endogenous pro-resolving mediator of inflammation, is derived from omega-3 fatty acid eicosapentaenoic acid (EPA). Resolvin E1 is endogenously biosynthesized from EPA in the presence of Aspirin during the spontaneous resolution phase of acute inflammation, where specific cell-cell interactions occur. Resolvin E1 possesses unique counterregulatory actions that inhibit polymorphonuclear leukocyte (PMN) transendothelial migration. Resolvin E1 also acts as a potent inhibitor of leukocyte infiltration, dendritic cell migration, and IL-12 production.
Isotope-Labeled Compounds   Endogenous Metabolite  
Inflammation or Immune System Disease  
/
HY-P10982 SjDX5-53
SjDX5-53 is a selective TLR2 inducer derived from a 3 kDa peptide from Schistosoma japonicum eggs. SjDX5-53 inhibits inflammatory Th1 and Th17 responses by inducing tolerogenic dendritic cells (tolDCs) and promoting the generation of regulatory T cells (Tregs) and their suppressive capacity. SjDX5-53 is primarily used in the treatment of autoimmune and inflammatory diseases such as colitis and psoriasis.
Toll-like Receptor (TLR)  
Inflammation or Immune System Disease  
/
HY-N0307R Ciwujianoside B (Standard)
Ciwujianoside B (Standard) is the analytical standard of Ciwujianoside B. This product is intended for research and analytical applications. Ciwujianoside B is an orally active, blood-brain barrier penetrable radioprotective agent and memory enhancer. Ciwujianoside B reduces radiation-induced DNA damage, cell cycle arrest and apoptosis, downregulates NF-κB and the Bax/Bcl-2 ratio, and enhances the proliferative capacity of bone marrow cells. Ciwujianoside B enhances object recognition memory in normal mice and induces dendritic extension in primary cultured cortical neurons. Ciwujianoside B can be used in studies related to hematopoietic system radiation injury and memory enhancement.
Reference Standards   Bcl-2 Family   NF-κB   DNA/RNA Synthesis   Apoptosis  
Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-183207 CD56 peptide/BSA
CD56 peptide/BSA is an antigen-adjuvant conjugate conjugate of CD56 peptide and BSA. By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and can enhance cross-presentation and the production of antigen-specific T cells.
Biochemical Assay Reagents  
/
HY-P10686 CH401 peptide
CH401 peptide is a HER2-derived antigen peptide. After being bound to the artificial viral capsid by a self-assembled β-cyclic peptide, CH401 peptide is encapsulated in a lipid bilayer containing the lipid adjuvant α-GalCer, and can be studied as a self-adjuvant anti-breast cancer vaccine candidate.
EGFR  
Cancer  
/
HY-P991800 Anti-Mouse Dendritic Cells Antibody (33D1)
Anti-Mouse Dendritic Cells Antibody (33D1) reacts with the mouse dendritic cells. Dendritic cells (DC) are a small subpopulation of lymphoid cells with distinctive cytologic features, surface properties, and functions. Recommend Isotype Controls: Rat IgG2b kappa, Isotype Control (HY-P990682).

Species: Mouse

Biochemical Assay Reagents  
Inflammation or Immune System Disease  
/
HY-W713010 3-Epideoxycholic acid-d5
3-Epideoxycholic acid-d5 is the deuterium labeled 3-Epideoxycholic acid (HY-48814). 3-Epideoxycholic acid is the microbial metabolite of Deoxycholic acid (HY-N0593). 3-Epideoxycholic acid targets FXR of dendritic cells, reduces their immunostimulatory properties, promotes the generation of Treg cells, and exhibits anti-inflammatory activity. 3-Epideoxycholic acid promotes the growth of bacteria Bacteroides.
Isotope-Labeled Compounds   Endogenous Metabolite   FXR  
Inflammation or Immune System Disease  
/
HY-P10295 p53 (232-240)
p53 (232-240) is a peptide segment of the 232-240 amino acid sequence of the human tumor suppressor protein p53. p53 (232-240) enhances its binding affinity to the Major histocompatibility complex (MHC), thereby enhancing the immunogenicity of this peptide to enhance the immune system's response to tumor antigens. p53 (232-240) can be used in the development of cancer vaccines and in the study of tumor cell recognition and clearance by the immune system.
MDM-2/p53  
/
HY-P5334 AADvac 1
AADvac 1 is an active tau peptide vaccine for Alzheimer's disease research. AADvac 1 is composed of a regulatory peptide 294KDNIKHVPGGGS305 that drives tau oligomerization conjugated to Aplysia hemocyanin (KLH) and formulated with aluminum hydroxide.
Others  
Neurological, Eye or Ear Disease  
/
HY-P1771 OVA G4 peptide
OVA G4 peptide is a variant of the agonist ovalbumin (OVA) peptide SIINFEKL (257-264). SIINFEKL is routinely used to stimulate ovalbumin-specific T cells and to test new vaccine adjuvants can form a stable hydrogel.
Biochemical Assay Reagents  
Inflammation or Immune System Disease  
/
HY-P10701 Q11 peptide
Q11 peptide is a β-sheet-forming peptide that plays an important role in self-assembly and targeted applications. As a scaffold peptide, Q11 peptide can display immunogenic epitopes and is widely used in peptide-based immune vaccine research. Additionally, Q11 peptide can be conjugated with MUC1 glycopeptides for the study of self-assembling, adjuvant-free MUC1 glycopeptide vaccines. Q11 peptide holds great potential for research in the field of cancer immunology.
Biochemical Assay Reagents  
Inflammation or Immune System Disease  
/
HY-NP0211 DHT-OVA
DHT-OVA is a conjugate of DHT (Dihydrotestosterone) and OVA peptide. By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt linear epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
Biochemical Assay Reagents  
Inflammation or Immune System Disease  
/
HY-P11059 MC38 SLP Reps1
MC38 SLP Reps1 is a peptide neoantigen generated by mutation of the MC38 colon cancer cell line and can be used for the synthesis of nanoparticle vaccines.
Others  
/
HY-169232 PCC16 chloride
PCC16 chloride is a dual PROTAC degrader targeting DHHC3 and PD-L1, with a DC50 of 0.103 μM for PD-L1 degradation. PCC16 chloride induces DHHC3 degradation via the ubiquitin-proteasome pathway by recruiting the CRBN E3 ubiquitin ligase (E3 ubiquitin ligase). By targeting DHHC3-which is essential for PD-L1 palmitoylation and membrane stability-PCC16 chloride reduces PD-L1 levels, decreases PD-L1 membrane retention time, and impairs its immunosuppressive function. PCC16 chloride enhances anti-tumor immunity by disrupting PD-L1-mediated immunosuppression. PCC16 chloride can be used in the research of immune checkpoint blockade-resistant cancers.
PROTACs   PD-1/PD-L1  
Cancer  
/
HY-163551 BNP peptide/KLH
The BNP peptide/KLH is an antigen-adjuvant conjugate formed by linking BNP peptide (human brain natriuretic peptide) with keyhole limpet hemocyanin (KLH). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or damage the major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
Others  
Inflammation or Immune System Disease  
/
HY-138170GL ALC-0315 (GMP Like)
ALC-0315 (GMP Like) is ALC-0315 (HY-138170) produced by using GMP like guidelines. GMP Like small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. ALC-0315 is an ionisable aminolipid that is responsible for mRNA compaction and aids mRNA cellular delivery and its cytoplasmic release through suspected endosomal destabilization. ALC-0315 can be used to form lipid nanoparticle (LNP) delivery vehicles. Lipid-Nanoparticles have been used in the research of mRNA COVID-19 vaccine.
Liposome   SARS-CoV  
Infection  
/
HY-131920 Poly(U)
Poly (U) (Polyuridylic acid) is an RNA chain that exists in a disordered extended state at room temperature and serves as a TLR7 ligand. Poly (U) produces distinguishable blocking effects when transported through α-hemolysin nanopores. Poly (U) forms a triple helix with adenosine or adenosine monophosphate, thereby significantly promoting the nucleotide bond condensation reaction between adenosine monophosphate and adenosine, while exerting minimal effects on other nucleosides. When conjugated with cationic lipids, Poly (U) specifically stimulates plasmacytoid dendritic cells to produce type I interferons.
Toll-like Receptor (TLR)  
Inflammation or Immune System Disease  
/
HY-P990046 Tuparstobart
Tuparstobart (Incagn-02385) is an IgG1κ antibody targeting LAG-3. LAG-3 is an immune checkpoint receptor protein mainly expressed on activated T cells, NK cells, B cells and plasmacytoid dendritic cells.

Species: Human

LAG-3  
Inflammation or Immune System Disease   Triple-Negative Breast Cancer  
/
HY-P11084 WT1 126-134 peptide
WT1 126-134 peptide is a Wilms' tumor oncogene protein (WT1) peptide (RMFPNAPYL). WT1 126-134 peptide is presented by HLA-A0201 and induces cytotoxic CD8 T cells capable of killing WT1+ positive tumor cells. WT1 126-134 can form stable complexes with the H-2Db (mouse) or HLA-A0201 (human) molecules. WT1 126-134 peptide/HLA-A0201 complex has an extremely high affinity (Kd = 0.2 nM) with the humanized monoclonal antibody (IgG1). WT1 126-134 peptide can be used as a vaccine for T cells or as a target for antibodies.
MHC  
Cancer   Inflammation or Immune System Disease  
/
HY-P11060 MC38 SLP Adpgk
MC38 SLP Adpgk (Adpgk peptide) is an H-2 Kb-restricted colorectal cancer neoantigen peptide. MC38 SLP Adpgk is formulated into PCNP nanocomplexes together with CpG ODN. PCNP vaccines significantly enhance the co-delivery efficiency of neoantigens and adjuvants to lymphoid organs, and activate cytotoxic T cells. PCNP vaccines not only protect mice from MC-38 colorectal tumor invasion, but also exhibit anti-tumor efficacy in established colorectal tumor models and significantly prolong the survival of tumor-bearing mice.
MHC  
Colorectal Cancer  
/
HY-134541G SM-102 (GMP)
SM-102 (GMP) is SM-102 (HY-134541) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SM-102 is an amino cationic lipid useful in the formation of lipid nanoparticles (LNPs). SM-102 has higher transfection efficiency. SM-102 plays an important role in the effectiveness of lipid nanoparticles (LNPs) in delivering mRNA therapeutics and vaccines.
Liposome  
Infection  
/
HY-N10116A Calamenene
Calamenene is a sesquiterpene compound. Calamenene promotes dendritic cell maturation, upregulates CD1a, CD80, CD83, CD86, HLA-DR and CCR7 on the cell surface, reduces endocytic activity, enhances T cell-stimulating capacity, drives Th1 polarization through the secretion of IL-12, induces IFN-γ production, decreases IL-4 generation, and triggers intracellular Ca2+ mobilization as well as dendritic cell migration towards MIP-3β. Calamenene exerts bacteriostatic and bactericidal growth-inhibitory effects against pathogenic *Vibrio harveyi*. Calamenene can be used in studies related to cancer and bacterial infections.
Interleukin Related   IFNAR   Calcium Channel   Bacterial   CCR  
Cancer   Bacterial Infection  
/
HY-N8840 Laricitrin
Laricitrin is a natural product with multiple biological activities. Laricitrin inhibits the phosphorylation and DNA-binding activity of STAT3, and downregulates the expression of IL-10. Laricitrin acts as an immunomodulator to regulate the differentiation, maturation and function of dendritic cells (DCs). Laricitrin inhibits the migration and invasion of lung cancer cells, and ameliorates lung cancer progression. Laricitrin can be used in research related to hypertension and lung cancer.
STAT   Interleukin Related  
Lung Cancer   Hypertension  
/
HY-P10762 Ricorfotide vedotin
Ricorfotide vedotin (CBP-1008) is a dual-ligand peptide-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. Ricorfotide vedotin binds to FRα with high affinity and TRPV6 with low affinity. Ricorfotide vedotin has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma).
Peptide-Drug Conjugates (PDCs)   Folate Receptor (FR)   TRP Channel  
Cancer  
/
HY-P10838A PL120131 acetate
PL120131 acetate is a PD-1 antagonist, can specifically blocking the interaction between PD-1 and PD-L1, thereby effectively inhibiting the PD-1-mediated apoptosis signaling pathway. PL120131 acetate rescues lymphocytes from apoptosis, maintains the survival and activity of T cells, and induces cytotoxic T lymphocytes to exert killing effects and recognize macrophages and dendritic cells. PL120131 acetate can be used in research related to breast cancer and various malignant tumors.
PD-1/PD-L1   Apoptosis  
Cancer  
/
HY-P2114 IT9302
IT9302 is a synthetic IL-10 agonist with the activity of inducing tolerogenic dendritic cells. IT9302 is able to mimic multiple effects of IL-10, including downregulating the antigen presentation machinery and increasing the sensitivity of tumor cells to natural killer cell-mediated lysis. IT9302 can also hinder the response of human monocytes to differentiation factors and reduce the antigen presentation and co-stimulatory capacity of dendritic cells. Dendritic cells treated with IT9302 showed a weakened ability to stimulate T cell proliferation and interferon-γ production. IT9302 exerts its effects through mechanisms that are partially different from IL-10, involving STAT3 inactivation and regulation of the NF-κB intracellular pathway. IT9302-treated dendritic cells showed enhanced expression of membrane-bound TGF-β, associated with the effective induction of foxp3+ regulatory T cells.
Others  
Cancer  
/
HY-P3486 GADGVGKSAL
GADGVGKSAL is a mutant KRAS G12D 10mer peptide. GADGVGKSAL can be used as an immunogenic neoantigen for cancer immunotherapy research.
Others  
Cancer   Inflammation or Immune System Disease  
/
HY-P3487 GAGGVGKSA
GAGGVGKSA is a wild type KRAS G12D 9mer peptide. GAGGVGKSA can be used as an immunogenic neoantigen for cancer immunotherapy research.
Others  
Cancer   Inflammation or Immune System Disease  
/
HY-134541GL SM-102 (GMP Like)
SM-102 (GMP Like) is SM-102 (HY-134541) produced by using GMP like guidelines. GMP Like small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SM-102 is an amino cationic lipid useful in the formation of lipid nanoparticles (LNPs). SM-102 has higher transfection efficiency. SM-102 plays an important role in the effectiveness of lipid nanoparticles (LNPs) in delivering mRNA therapeutics and vaccines.
Liposome  
Infection  
/
HY-P3488 GADGVGKSA
GADGVGKSA is a mutant KRAS G12D 9mer peptide. GADGVGKSA can be used as an immunogenic neoantigen for cancer immunotherapy research.
Others  
Cancer   Inflammation or Immune System Disease  
/
HY-P11058 OVA(250-264)
OVA(250-264) (OVAvac) (OVAp) is an antigen peptide that can be from ovalbumin (OVA) presented by the class I MHC molecule, H-2Kb. OVA(250-264) combined withαMSLN (anti-MSLN antibody) significantly induces antigen-specific CD8+ T cell generation and infiltration for enhancing antitumor efficacy in orthotopic pancreatic cancer mice model. OVA(250-264) can be used for neoantigen vaccine development in pancreatic cancer immunotherapy research.
MHC  
/
HY-P11303 PADRE peptide
PADRE peptide is a pan-HLA-DR binding epitope and immunostimulant. PADRE peptide binds to the peptide-binding groove of MHC class II molecules for presentation to CD4+ T cells, thereby effectively stimulating specific immune responses. PADRE peptide not only enhances anti-tumor immune responses, inhibits tumor growth and prolongs survival; it also significantly increases the frequency of E7-specific CD8+ T cells and improves therapeutic efficacy against TC-1 tumors when used in combination with E7 peptide-based vaccines and poly (I:C). The intensity of the immune response induced by PADRE peptide is lower than that of the Ii-PADRE DNA vaccine, and it fails to enhance the immune effect of CRT-E7 DNA. PADRE peptide is widely applicable to research on related tumors such as melanoma, glioblastoma and cervical cancer.
CD74   MHC  
Cervical Cancer   Glioblastoma  
/
HY-P990068 Perenostobart
Perenostobart (SRF617) is a human IgG4 antibody with inhibitory activity against CD39 ATPase. Perenostobart inhibits CD39-mediated hydrolysis of extracellular ATP to AMP, with IC50 values of 1.9 nM (HEK293 OE cells), 0.7 nM (MOLP-8 cells), and 1.2 nM (RBC-lysed whole blood). Perenostobart enhances CD4+ T-cell proliferation, promotes dendritic cell maturation, and boosts inflammasome activation in macrophages in the presence of ATP. Perenostobart demonstrates significant single-agent anti-tumor efficacy in MOLP-8 and H520 xenograft models. Perenostobart can be used for the study of cancer.

Species: Human

NTPDase  
Cancer   Inflammation or Immune System Disease  
/
HY-145973A 3'OMe-m7GpppAmpG ammonium solution (100 mM)
3’OMe-m7GpppAmpG (m7(3'OMeG)(5')ppp(5')(2'OMeA)pG) ammonium solution (100 mM) is a trinucleotide Cap1 analog with the structure m7 (3'OMeG)(5') ppp (5')(2'OMeA) pG, and also functions as a cis-acting ligase ribozyme inhibitor. 3’OMe-m7GpppAmpG ammonium solution (100 mM) effectively reduces free 5'-triphosphate groups on RNA transcripts, thereby enabling efficient co-transcriptional capping of in vitro transcribed mRNA. 3’OMe-m7GpppAmpG ammonium solution (100 mM) is not only widely used in the preparation of modified mRNA including trivalent influenza vaccine candidates, but also applicable to studies related to SARS-CoV-2 infection and other relevant research.
Nucleoside Antimetabolite/Analog   SARS-CoV  
/
HY-N15135 Arabinoxylan (Medium viscosity)
Arabinoxylan Medium viscosity is an orally active Dectin-1 splice variant modulator, glucose absorption inhibitor, and chyme viscosity enhancer. Arabinoxylan Medium viscosity inhibits particulate β-glucan-induced Dectin-1A activation and mildly suppresses Dectin-1B activation. In human dendritic cells stimulated with particulate β-glucan, Arabinoxylan Medium viscosity reduces the production of IL-10 and TNF-α, and increases the production of IL-4 and IL-23. Arabinoxylan Medium viscosity also supports antifungal immune responses without activating TLR2, TLR4 or TLR5, and does not induce cytokine production when used to stimulate human dendritic cells alone. Arabinoxylan Medium viscosity increases small intestinal chyme viscosity, gets degraded in the large intestine to produce short-chain fatty acids, reduces glucose absorption and insulin response, and improves glucose homeostasis. Arabinoxylan Medium viscosity supports microbial fermentation and the growth of beneficial microbiota in the gastrointestinal tract, prevents bile acid reabsorption, and delays starch digestion. Arabinoxylan Medium viscosity can be used in research related to type 2 diabetes, impaired glucose tolerance, and metabolic syndrome.
Interleukin Related   Toll-like Receptor (TLR)   Fungal   C-type Lectin-like Receptors (CTLRs)  
Glucose Metabolism  
/
HY-P1771A OVA G4 peptide TFA
OVA G4 peptide TFA is a variant of the agonist ovalbumin (OVA) peptide SIINFEKL (257-264). SIINFEKL is routinely used to stimulate ovalbumin-specific T cells and to test new vaccine adjuvants can form a stable hydrogel.
Biochemical Assay Reagents  
Inflammation or Immune System Disease  
/
HY-D1056C3 Lipopolysaccharides, from S. enterica serotype typhimurium
Lipopolysaccharides, from S. enterica (Salmonella enterica) serotype typhimurium are lipopolysaccharide endotoxins and TLR4 activators derived from serotype typhimurium of Salmonella enterica, and are classified as S-type LPS. Lipopolysaccharides, from S. enterica exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Lipopolysaccharides, from S. enterica serotype typhimurium can modulate the fate of bacteria in dendritic cells (DC), determining the uptake, degradation, and activation of immune functions by DC cells against the bacteria.
It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.
Toll-like Receptor (TLR)  
Inflammation or Immune System Disease  
/
HY-107202GL Polyinosinic-polycytidylic acid (GMP Like)
Polyinosinic-polycytidylic acid (Poly(I:C)) (GMP Like) is the GMP Like class Polyinosinic-polycytidylic acid (HY-107202), and can be used as pharmaceutical excipients. Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid can directly trigger cancer cells to undergo apoptosis.
Toll-like Receptor (TLR)   PKD   HSP   Bcl-2 Family   Interleukin Related   Apoptosis  
Infection   Inflammation or Immune System Disease  
/
HY-P990273 Anti-Mouse CD38 Antibody (NIMR5)
Anti-Mouse CD38 Antibody (NIMR5) is an anti-mouse CD38 IgG2a monoclonal antibody. Anti-Mouse CD38 Antibody (NIMR5) can activate the ERK signaling pathway and promote cell apoptosis. Anti-Mouse CD38 Antibody (NIMR5) can restore T cell function. Anti-Mouse CD38 Antibody (NIMR5) upregulates the expression of CD1d protein and enhances spleen cell proliferation, dendritic cell (DC) and natural killer T cell (NKT) expansion. Anti-Mouse CD38 Antibody (NIMR5) can be used for researches on cancer and immunology such as melanoma and colon cancer.

Species: Mouse

CD38   ERK   CD1   Apoptosis  
Colorectal Cancer   Melanoma  
/
HY-B1618R Corticosterone (Standard)
Corticosterone (Standard) is the analytical standard of Corticosterone. This product is intended for research and analytical applications. Corticosterone (17-Deoxycortisol) is an orally active and adrenal cortex-produced glucocorticoid, which plays an important role in regulating neuronal functions of the limbic system (including hippocampus, prefrontal cortex, and amygdala). Corticosterone increases the Rab-mediated AMPAR membrane traffic via SGK-induced phosphorylation of GDI. Corticosterone also interferes with the maturation of dendritic cells and shows a good immunosuppressive effect.
Reference Standards   Glucocorticoid Receptor   Endogenous Metabolite   iGluR  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-P3333 KSPWFTTL
KSPWFTTL is an immunodominant Kb-restricted epitope from the p15E transmembrane protein. KSPWFTTL can restore susceptibility of a tumor line to anti-AKR/Gross MuLV cytotoxic T lymphocytes.
MHC  
Cancer   Inflammation or Immune System Disease  
/
HY-P99234 Pivekimab
Pivekimab is a human IgG1 monoclonal antibody that targets interleukin-3 (IL-3) and CD123. Pivekimab is used to synthesize pivekimab sunirine, a CD123-directed antibody-active molecule conjugate (ADC). Pivekimab is used in the study of blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Species: Human

Interleukin Related   ADC Antibodies  
Acute Myeloid Leukemia  
/
HY-P1587 IRBP (1-20), human
IRBP (1-20), human contains a major epitope for the H-2b haplotype. IRBP (1-20), human induces experimental autoimmune uveoretinitis (EAU) in H-2b mice.
MHC  
Inflammation or Immune System Disease  
/
HY-P4193 AH1
AH1 is an immunodominant MHC class I-restricted nonamer peptide recognized by CD8+ cytotoxic T lymphocytes. AH1 derives from the envelope protein (gp70) of an endogenous ecotropic murine leukemia virus and is presented by the MHC class I Ld molecule. AH1 can be used for the research of colorectal carcinoma.
MHC  
Cancer   Inflammation or Immune System Disease  
/
HY-P9990 Litifilimab
Litifilimab (BIIB059) is a humanized IgG1 monoclonal antibody targeting BDCA2. Litifilimab induces internalization of BDCA2 receptors on the membrane of plasmacytoid dendritic cells, inhibits the TLR7/TLR9 signaling pathway, and suppresses the production of type I interferons. Litifilimab can be used in the research of systemic and cutaneous lupus erythematosus.

Species: Human

C-type Lectin-like Receptors (CTLRs)   Toll-like Receptor (TLR)  
Systemic Lupus Erythematosus  
/
HY-124004 Acetyl-6-formylpterin
Acetyl-6-formylpterin (Ac-6-FP) is a hapten that stabilizes MR1 on antigen-presenting cells, forming an MR1:A6FP complex that fails to activate MAIT cell TCR, thereby acting as a competitive inhibitor of MAIT cell activation. Acetyl-6-formylpterin exacerbates house dust mite-induced airway hyperresponsiveness and elevates circulating IgE levels. Acetyl-6-formylpterin reduces systemic MAIT cell activity and decreases the frequency of IL-17A+ and IFNγ+ MAIT cells in the spleen. Acetyl-6-formylpterin is useful for the study of allergic asthma.
MHC   Interleukin Related   IFNAR  
Allergic Asthma  
/
HY-P991028 Surovatamig
Surovatamig (AZD0486; TNB-486) is a fully human anti-CD19/CD3 IgG4 bispecific antibody. Surovatamig triggers T cell activation, releases cytotoxic granules, and induces T cell-dependent cellular cytotoxicity and tumor cell lysis. Surovatamig can reduces release of pro-inflammatory cytokines including IL-2, IFNγ, TNF. Surovatamig can be used for the research of cancer, such as B cell non-Hodgkin lymphoma.

Species: Human

CD3   CD19   Interleukin Related   TNF Receptor   IFNAR  
Non-Hodgkin Lymphoma  
/
HY-P991015 Pasritamig
Pasritamig (JNJ-78278343; KLCB-245) is a bispecific T-cell engager (BiTE) that targets the complex of human kallikrein KLK2 and CD3 receptor. Pasritamig redirects the cytotoxicity of T cells to KLK2-expressing tumor cells and induces T cell-mediated lysis of KLK2-expressing prostate cancer cells. Administered via subcutaneous injection, subcutaneous infusion or intravenous infusion, Pasritamig exhibits antitumor activity against metastatic castration-resistant prostate cancer. Pasritamig has a safety profile with an extremely low incidence of cytokine release syndrome and can be safely administered in an outpatient setting. Pasritamig is applicable to the research of metastatic castration-resistant prostate cancer.

Species: Human

CD3  
Castration-Resistant Prostate Cancer  
/
HY-P9954 Catumaxomab
Catumaxomab, a trifunctional IgG2 antibody, is composed of mouse and rat heavy and light chains and binds to human EpCAM and human CD 3 receptors. The Fc region of Catumaxomab region has binding affinity for FcγR1 (CD 64), FcγRIIA (CD 32a), and FcγRIII (CD 16). Catumaxomab can be used for anti-tumor research, especially epithelial cancers.

Species: Human

CD3  
Gastric Cancer   Ovarian Cancer  
/
HY-P990688 Xaluritamig
Xaluritamig (AMG-509) is a bispecific T cell engager and cytolytic agent with a Kd of 27.6 nM for human CD3ε. Xaluritamig binds to CD3ε via an anti-CD3 single-chain variable fragment (scFv) domain, and to STEAP1 via a bispecific anti-STEAP1 antigen-binding fragment (Fab) domain, thereby recruiting and activating T cells and forming a bridge between T cells and STEAP1-expressing cancer cells. Xaluritamig induces T cell-mediated redirected cytotoxicity, tumor cell lysis, cytokine release, CD8+ T cell activation and expansion, as well as tumor stasis or regression. Xaluritamig contains an Fc domain with no effector function, which prolongs serum half-life, exhibits only minimal activity against cells with low STEAP1 expression and normal cells, and shows extremely low target-related off-tumor toxicity in cynomolgus monkeys. Xaluritamig is used in STEAP1×CD3 XmAb 2+1 immunotherapy and in research on metastatic castration-resistant prostate cancer and Ewing sarcoma.

Species: Human

CD3  
Castration-Resistant Prostate Cancer  
/
HY-P99392 Teclistamab
Teclistamab is a human bispecific antibody to BCMA and CD3 that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM).

Species: Human

CD3  
Cancer  
/

Keywords

cancer vaccines | neoantigens | mRNA vaccines | dendritic cells | peptide vaccines | immune checkpoint blockade